ArticlePhysiological research2026
Adipocytokine Profiles in Type 2 Diabetes Mellitus and Autoimmune Thyroid Disease: Associations With Metabolic and Hormonal Parameters.
Article in Physiological research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) and autoimmune thyroid disease (AITD) are complex disorders involving metabolic, immune, and hormonal dysregulation. Adipocytokines from adipose tissue influence metabolism, inflammation, and immune regulation. We investigated adiponectin, resistin, and visfatin in relation to thyroid, glucose, and metabolic parameters in adults with T2DM, AITD, both conditions, and healthy controls. A total of 385 adults were recruited. Clinical, anthropometric, and laboratory parameters were assessed, including glycemia, glycated hemoglobin (HbA1c), free thyroxine (fT4), thyroid-stimulating hormone (TSH), thyroid antibodies, and serum levels of adiponectin, resistin, and visfatin. Correlation and regression analyses were performed, including models adjusted for age, sex, and BMI. Adiponectin was higher in AITD than T2DM (p=0.012), resistin was higher in T2DM&AITD than controls (p=0.004), and visfatin was lower in T2DM than other groups (p<0.001). In T2DM&AITD, adiponectin correlated positively with age and fT4 and negatively with BMI (p=0.028, p=0.034). Resistin correlated inversely with TSH in AITD (p=0.033). Visfatin correlated inversely with thyroid volume in T2DM (p=0.003) and with waist circumference in AITD and T2DM&AITD (p=0.007, p=0.020). After adjustment, resistin remained higher in T2DM&AITD vs. controls (p=0.013) and visfatin and adiponectin remained lower in T2DM vs. controls (p=0.049 and p=0.045, respectively). This study highlights distinct adipocytokine profiles in individuals with metabolic and autoimmune thyroid conditions. Adiponectin, resistin, and visfatin may be potential biomarkers for disease severity and metabolic dysfunction. Further research is needed to elucidate the mechanistic pathways linking adipocytokines to the pathophysiology of T2DM and AITD. Key words Type 2 diabetes mellitus " Autoimmune thyroid disease " Adipocytokines " Metabolic dysfunction.
Indexed as
Identifiers
42455070PMC13557541What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.